The Ozempic Era Is Ending. Here's What Replaces It.

The five-axis fragmentation, at a glance

• **Cleanliness:** Stanford's BRP, an endogenous peptide that targets the hypothalamus and skips the gut entirely.
• **Magnitude:** Eli Lilly's retatrutide, approaching ~28.7% body weight reduction in TRIUMPH-4 Phase 3.
• **Cardio-protection:** tirzepatide showing ~20% lower MACE risk vs dulaglutide in real-world Cleveland Clinic data.
• **Mechanism elegance:** biased-signaling agonists like NNC5840 outperforming semaglutide in mice through smarter receptor design, not louder.
• **Category expansion:** multi-omic and editorial signals reframing the entire GLP-1 class as longevity drugs, not just weight-loss drugs.

That's the map. Now the territory.

* * *

1\. Ozempic Was a Breakthrough, and a First Draft

It is genuinely difficult, in 2026, to remember how recently the obesity conversation lived almost entirely in the moral and behavioral register. Calories in, calories out. Willpower. Discipline. A patient with a BMI of 38 walked into a clinic and walked out with the same advice they could have gotten from a magazine. The pharmacological options were embarrassing: a few stimulants with edges sharp enough that most physicians refused to prescribe them, a couple of lipase inhibitors with a side-effect profile so gruesome it functioned as accidental aversion therapy, and a small number of older drugs that had to be repurposed off-label.

Then, almost without warning, semaglutide changed the entire field in eighteen months.

The story has been told so many times it has acquired the smooth quality of mythology. Novo Nordisk, sitting on a diabetes drug originally optimized for glycemic control, watched the Phase 3 weight signal with growing astonishment. The STEP trials landed. Trial participants on the highest dose lost roughly 15% of body weight over 68 weeks, a number so far above what any prior pharmacotherapy had achieved that endocrinologists who had spent careers managing modest expectations had to recalibrate the conversation in real time.

Several things happened almost simultaneously. The cardiovascular community got the SELECT trial: a 20% reduction in major adverse cardiovascular events in patients with overweight or obesity and established cardiovascular disease, in patients without diabetes. Hepatology started to see meaningful liver-fat reduction. Nephrology got the FLOW trial signal. Sleep medicine watched apnea scores drop. And the supply-and-demand mismatch produced a gray-market secondary economy in research peptides that, by any rational read, will be remembered as one of the strangest health-consumer stories of the decade.

So this is not a takedown piece. Semaglutide is, in any honest accounting, one of the most important pharmacological achievements of the last twenty years. It moved the obesity conversation from willpower to biology, from individual character to receptor pharmacology, in the span of two FDA decisions.

And yet.

The same trials that anchored semaglutide as a category-defining drug also marked, with quiet precision, the boundaries of what a single molecule operating through a single receptor can do. The weight-loss curve in STEP plateaus around 15% in most patients. The dropout rate, which the cultural narrative tends to elide, is significant. The lean-mass loss, which DEXA studies have now characterized in painful detail, runs at roughly 25 to 40% of total weight lost. There is a non-responder tail nobody talks about. Adherence at twelve months is much lower than the headline numbers suggest. Rebound weight regain in the year after discontinuation is now well-documented enough to be the basis of a new clinical category: chronic GLP-1 maintenance therapy, with all the lifelong-medication implications that phrase implies.

None of this is a scandal. It is what happens to every first-generation blockbuster in every category. The first SSRI, the first statin, the first PD-1 inhibitor: each one shocked the field with effect sizes that reset expectations, then, over the following decade, slowly revealed the limitations that the next generation was built to fix.

**Ozempic isn't ending because it failed. It's ending because it succeeded, and exposed the next set of bottlenecks.**

!Sledgehammer on lab counter with broken glass

* * *

2\. Why the Field Is Fragmenting

Here is the central observation that organizes everything that follows. "Obesity," as a clinical label, is one word laid across a startling number of distinct biological problems.

Two patients can both arrive at a BMI of 35 by completely different routes. One has a hyperactive appetite drive: every meal is the first meal, satiety signals never quite arrive, food is on her mind from the moment she wakes up. Another has perfectly normal hunger but a metabolic rate that runs unusually low, an insulin response that turns every carbohydrate into stored fat with ruthless efficiency, and a body that defends a higher set point with hormonal countermeasures every time he tries to lose weight. A third has a reward system wired such that food provides a kind of relief that nothing else does, and the obesity is downstream of an affective and behavioral pattern that no monotherapy can touch. A fourth carries a meaningful genetic load in pathways that influence energy expenditure and lipid handling and is, in some real sense, swimming against a current the other three are not.

The same diagnosis. Five different diseases. And until recently, all five would have been handed the same prescription.

The fragmentation that defines Act 2 of the GLP-1 era is not a marketing artifact or a pipeline accident. It is the field doing what every maturing therapeutic area eventually does: splitting into specialized tools, each optimized for one of the underlying biological drivers that the first-generation drug was forced to treat as a single problem.

The point is not that one of these molecules is going to win and replace Ozempic the way Ozempic replaced what came before. The point is that none of them are. The field is not converging on a successor. It is diverging into a menu.

And once a menu exists, the question that sits in front of the patient, the clinician, and the genuinely curious reader stops being "What is the best drug?" and becomes "Which drug for me?"

* * *

3\. Chapter One: More Force

The first axis along which the field has fragmented is the most obvious one: efficacy. If Ozempic ceilings around 15% body-weight reduction, what happens when you stop activating one receptor and start activating two, or three?

Two molecules anchor this story, and they are usefully understood as a pair: tirzepatide, which proved that adding a second incretin receptor to the mix yields more than additive benefit, and retatrutide, which adds a third and approaches the magnitude that previously required a surgeon.

!Two molecular ribbon structures, dual and triple agonism

3A. Tirzepatide: The First Real Fracture in the Monoculture

**Evidence Tier: Real-World Human Outcomes**

Tirzepatide was the first sign that the single-receptor era was not going to last. By coupling agonism at the GLP-1 receptor with simultaneous agonism at the GIP receptor, Eli Lilly produced a molecule whose efficacy in trial conditions exceeded semaglutide by a margin too large to dismiss as noise. SURMOUNT-1 reported mean weight loss approaching 20% at the highest dose. SURPASS demonstrated glycemic control superior to several active comparators.

In 2026, the Cleveland Clinic published a real-world analysis comparing tirzepatide and dulaglutide in approximately fifteen thousand patients with type 2 diabetes drawn from electronic health records. The headline finding: a roughly 20% lower risk of major adverse cardiovascular events on tirzepatide versus dulaglutide. The dataset is observational and the comparator is not semaglutide, so the usual real-world-data cautions apply. None of which negates the underlying signal. Adding GIP agonism on top of GLP-1 agonism appears to do something for cardiovascular risk that pure GLP-1 monotherapy may not fully replicate.

The reason this matters for the fragmentation thesis is that it shifts the scoreboard. Ozempic-era conversations were dominated by a single number: body weight, expressed as a percentage. The tirzepatide story drags the conversation toward a different number: events prevented.

> **Genetic Matching Hypotheses, Tirzepatide.** The published literature has flagged variants in _GLP1R_, _GIPR_, _TCF7L2_, and _MC4R_ as candidate modulators of incretin response. The Cleveland Clinic dataset, like every population-scale incretin analysis, contains a tail of patients with no measurable cardio-protective signal. The open question is not _whether_ genetics modulates response. It is _how much_, and _for which endpoints_.

3B. Retatrutide: When Pharmacology Approaches Bariatric Territory

**Evidence Tier: Phase 3 Trial Efficacy**

If tirzepatide opened the door, retatrutide is what walked through it.

The molecule is a triple agonist: GLP-1, GIP, and glucagon. The first two are familiar. The third, glucagon, is the one that ought to make you sit up. For most of the modern history of metabolic medicine, glucagon receptor activation was a direction the field _avoided_, on the entirely reasonable grounds that glucagon raises blood glucose and we have spent the better part of a century trying to lower blood glucose. The story of how that prejudice broke is a small masterpiece of pharmacological reframing. Glucagon receptor activation, particularly in liver and adipose tissue, also raises energy expenditure: meaningfully, measurably, in a way that a calorie balance equation has to acknowledge.

The Phase 2 readout already signaled that retatrutide was operating in a different category: mean weight loss in the 24% range at the highest dose, a number that until recently was the exclusive territory of bariatric surgery. The Phase 3 program, branded TRIUMPH, began reporting in 2026, and the early TRIUMPH-4 readout has been widely described in the trade literature as approaching 28.7% body weight reduction at the top dose over the trial's primary endpoint window.

!Vintage scale weighted with a brass cylinder

What does that actually mean? A 28% reduction in body weight is not "more weight loss" in the sense that a 17% reduction is more than a 12% reduction. It is a structural change in the kinds of patients for whom pharmacotherapy is a credible alternative to surgery. Sleep apnea that resolves rather than improves. Hepatic steatosis that reverses rather than retreats. Heart failure with preserved ejection fraction beginning to look like something that might respond to sufficiently aggressive metabolic intervention.

Triple agonism asks more of the body than monotherapy. Gastrointestinal tolerability gets harder, not easier, at the highest doses. The muscle-sparing data is still maturing. There is a real physiological argument about receptor downregulation and what hitting three pathways at maximum dose may do to the body's endogenous signaling architecture over years of continuous use.

The thesis-confirming move is to notice what retatrutide does to the conversation. For two decades, every new obesity drug was evaluated against a baseline of "modest improvement on what came before." Retatrutide is the first credible argument that pharmacotherapy could compete with bariatric surgery on the only metric surgery has historically won: sheer magnitude of effect. (See also: Brenipatide, the once-monthly drug coming after retatrutide.)

> **Genetic Matching Hypotheses, Retatrutide.** Glucagon receptor variants ( _GCGR_) are an obvious starting point, as are loci tied to energy expenditure and mitochondrial efficiency: _FTO_, _MC4R_, the _UCP_ family. The muscle-preservation question becomes more salient at 28% weight loss than at 15%; variants in pathways governing protein turnover, satellite-cell biology, and anabolic signaling may matter much more in the retatrutide-eligible patient than they did in the semaglutide-eligible patient.

* * *

4\. Chapter Two: More Precision

If the first chapter is about how much force you can apply, the second is about how cleanly you can apply it.

4A. BRP: The Endogenous Hypothalamic Scalpel

**Evidence Tier: Preclinical / Translational Hypothesis**

In April 2026, a team at Stanford led by Katrin Svensson published in Nature a finding that, depending on how it translates to humans, may turn out to be one of the most significant peptide discoveries of the decade. The molecule is called BRP (BRINP2-related peptide), and the way it was found is almost as important as what it does.

The Svensson group built an artificial intelligence pipeline they called Peptide Predictor and trained it on a question the field had not previously known how to ask in a systematic way: of all the human protein-coding genes, which encode short peptides that look, by structural and contextual signature, like they should be acting as endogenous appetite-modulating signals? The AI did not generate novel molecules. It generated _predictions about which already-existing endogenous human peptides we had simply failed to notice_.

BRP came out of that pipeline. In animal studies, it suppresses appetite and reduces body weight with effect sizes that are, in early reads, comparable to the GLP-1 class. The mechanism appears to be central. BRP acts on neurons in the hypothalamus, the brain region that integrates satiety, hunger, and energy-balance signaling. The animal data suggests that BRP's action is largely confined to those central feeding circuits. It does not appear to engage the vagal and peripheral pathways that mediate the gastrointestinal punishment of GLP-1 agonism. It does not appear to drive the lean-mass loss that has become the quiet anxiety underneath the Ozempic boom.

!Glowing teal cross-section of human head with hypothalamus highlighted

If the human translation works the way the preclinical data suggests it might, BRP is the answer to the question that millions of Ozempic users are asking but rarely articulating cleanly: _what if we could get the appetite benefit without feeling wrecked?_

It would be the worst kind of writing to leave that paragraph without the necessary caution. BRP is preclinical. The translation from rodent appetite biology to human appetite biology is not a solved problem. The pharmacokinetics of getting an endogenous peptide to behave usefully as a therapeutic are non-trivial engineering problems that have killed many promising candidates. Anyone selling you BRP-based products in 2026 is selling you something that does not yet exist as a validated human therapy.

The structural significance is what is real now. The fact that an AI-driven endogenous-peptide-discovery pipeline produced a credible candidate this fast, in a field most researchers assumed had been thoroughly mapped, suggests that the search space for the next generation of metabolic and longevity peptides may be much larger than anyone thought. BRP is the first clear datapoint. It will not be the last.

> **Genetic Matching Hypotheses, BRP.** Endogenous peptides have endogenous regulation. Baseline BRP expression varies across individuals. The genetic architecture of central appetite control (variants near _MC4R_, _POMC_, _LEPR_, _NPY_) has been mapped well enough to suggest plausible response heterogeneity. If BRP translates to humans, the people who benefit most may be those whose endogenous appetite-suppression machinery is, for genetic reasons, muted.

4B. NNC5840: Smarter, Not Louder

**Evidence Tier: Preclinical / Mechanistic**

The other half of the precision story is harder to translate but, intellectually, may be the most important section in this entire article.

The general reader does not need a graduate-level pharmacology lecture to follow this. They need one fact: G-protein-coupled receptors, the family the GLP-1 receptor belongs to, are not on-off switches. When an agonist binds, it can activate multiple downstream signaling cascades, most importantly the cAMP cascade and the β-arrestin cascade, and the relative strength of each cascade is a function of how the agonist sits in the receptor pocket.

NNC5840, the placeholder identifier for a class of molecules being developed by Novo Nordisk and several academic groups, is one example of what biased signaling looks like in practice. The mechanistic profile favors cAMP signaling and substantially reduces β-arrestin recruitment. In mouse studies, that biased profile produces greater weight loss than equivalent doses of semaglutide. Not because more receptors are being activated. Because the right downstream cascades are being activated and the wrong ones are not.

The reason this section matters even for readers who will never take NNC5840 is that it changes what next-generation peptide design _looks like_. The first decade of GLP-1 development was a magnitude race. The next decade is going to be a precision race. The implication for the patient is not that NNC5840 is the right answer for them. The implication is that "more agonism is better" is going to age very poorly as a default assumption.

* * *

5\. Chapter Three: Bigger Ambition

The third chapter is the philosophical twist of the article. Up to this point, the entire conversation has been organized around obesity. But there is a parallel conversation building in the longevity and geroscience literature that, if it pans out the way its early signals suggest, will eventually swallow the obesity framing entirely.

5A. GLP-1 as a Longevity / Systems Platform

**Evidence Tier: Multi-Omic Association + Editorial Position**

In April 2026, Cell Metabolism published a multi-omic analysis of GLP-1 receptor agonist effects across organ systems that, in the careful language scientists use when they suspect they are looking at something larger than the immediate hypothesis, characterized the changes as "body-wide" and "consistent with broad anti-aging signatures." The signal across that combined readout was not subtle. The molecular changes characteristic of GLP-1 receptor agonism look, in many tissues, like the molecular changes that aging researchers have been chasing for two decades as candidate biomarkers of slowed biological aging.

!Stylized human silhouette with multiple organ systems glowing teal

Two months earlier, Nature Health ran an editorial making the case that the GLP-1 receptor agonist class deserves rigorous evaluation as a longevity therapeutic, not just a metabolic one. It does not claim lifespan extension has been proven. It argues, instead, that the volume and consistency of multi-system signals now exceeds what the obesity-and-diabetes framing can accommodate, and that the field needs to design and run trials that take longevity endpoints seriously.

Translate that into the framework this article has been building, and the implication is striking. If GLP-1 receptor agonism (and by extension the dual and triple agonists, and possibly the cleaner endogenous peptides like BRP) operates as a class of geroscience interventions rather than a class of weight-loss drugs, then the population for whom these molecules might matter is much larger than the population that currently qualifies for them under any obesity- or diabetes-based prescribing guideline.

The lean optimizer who is not overweight but cares deeply about cardiovascular and metabolic aging. The longevity-curious clinician who has been watching the rapamycin and metformin off-label scenes with one eye and quietly wondering whether the GLP-1 class belongs in the same conversation. These are not Ozempic patients in any conventional sense, and they have been told, mostly correctly, that the drug is not for them. The longevity reframing changes that conversation.

The longevity story is a reframe, not a verdict. But it is a serious reframe, made by serious people in serious journals, and it changes who the matching problem is for.

* * *

6\. The Real Bottleneck Is No Longer Discovery. It Is Matching.

Let us return to the cold open and finish what we started.

The 47-year-old founder who lost 19% on semaglutide and felt his motivation dial turn down has, in the framework this article has built, a clear answer: he is in the wrong drug. His primary axis is not magnitude. He needs the cleanliness axis. If BRP translates to humans the way its preclinical data suggests, he is exactly the patient it was made for.

The cardiometabolic patient who is not enormously overweight but whose family history is studded with early heart attacks does not need maximum weight loss either. He needs the cardio-protection axis. Tirzepatide, with its real-world MACE signal and its dual-incretin profile, looks meaningfully different from semaglutide for him.

The patient with severe obesity, whose comorbidities are stacking and whose surgical option is increasingly the topic of conversation, needs the magnitude axis. Retatrutide, with its approaching-bariatric efficacy, may be the molecule that allows them to avoid surgery, or shrinks the surgery they end up needing.

The mechanism-curious optimizer may end up benefiting most from the biased-signaling story, not because they will take NNC5840 in 2027 but because the molecules that come out of that research program over the next decade are likely to be the ones that get the side-effect profile right for indefinite-duration use in metabolically healthy people.

The longevity-curious early adopter may not need any of these molecules in the conventional sense. They are participating in a slowly-emerging conversation about whether the entire GLP-1 class belongs in the same off-label longevity stack as rapamycin and metformin.

Five patients. Five drugs. Five different right answers.

**When there are five right answers, the real question is no longer "What is the best drug?" The real question is "Which drug for me?"**

That question has historically been answered by clinical trial-and-error. For a category fragmenting this fast, into this many specialized molecules, with this many distinct side-effect profiles, trial-and-error is going to look increasingly like flying blind.

* * *

7\. Where Genetics Enters, and Where It Doesn't

It is important to be honest about what genetics can and cannot do for the matching problem.

Genetics cannot tell you which drug will work for you with deterministic certainty. The variance in metabolic response that any current panel can explain is a slice of total variance, not the whole pie. Tolerability, dosing schedule, adherence, access, lifestyle context, comorbid conditions, drug-drug interactions, and the lived response a patient develops over months on a given molecule all matter. Anyone selling genetics as a deterministic prescription engine is overselling. We will not be that person.

What genetics _can_ do, for a category as fragmented as this one is becoming, is add a layer of biological context to a multi-variable decision that currently has too few inputs.

!Saliva tube with DNA strand transforming into peptide ribbons

That layer is what we have built at The Peptide List. Our saliva DNA Kit reads **111 SNPs** with replicated associations across the metabolic and peptide-response pathways that the next decade of fragmentation will turn on. The kit is non-invasive (a saliva sample, not a blood draw) and the output, the **Peptide Genetics Report**, is structured around the matching problem this article has been describing. It does not dictate a prescription. It does not replace a clinician. It does not pretend to predict a response that the underlying science cannot predict. What it does is sit alongside the rest of the decision inputs (labs, body composition, history, patient priorities) as one more layer of biological context, contributed by the one variable in the equation that is fixed for the rest of your life and that, until very recently, was largely invisible to the prescribing decision.

The framing we use internally is the same framing we use externally: as the menu fragments, the value of any single decision-support layer goes up. In the era this article has been describing, where five distinct axes each have a leading molecule and the right answer for any given patient depends on which axis they actually need to optimize, the genetic question stops being interesting and starts being practical. (For the longer treatment of how DNA shapes peptide response, see Your DNA already knows which peptides will work for you.)

* * *

8\. What a Smart Skeptic Would Say

The first skeptic looks at the structure of the argument and says: _You are comparing apples to oranges across radically different evidence tiers and then selling personalization as the solution to immaturity that has not been validated yet._

This is a fair critique. Yes, the evidence tiers across the five storylines are different, which is exactly why every section in this article carries an evidence-tier badge. The fragmentation argument does not require them to be the same level of evidence. It only requires that each axis is real enough to make "best drug for me" a different question than "best drug overall," and on that narrower point, all five axes clear the bar.

The deeper version of the skeptic's argument is that personalization-as-solution is being sold prematurely. The honest response is that the cost of mismatch rises as the menu fragments. In a world with one drug, the matching problem is invisible. In a world with five distinct molecules each optimized for a different axis, the cost of being on the wrong one for a year is much larger than it used to be. Personalization is not being sold as perfect prediction. It is being offered as a Bayesian prior that becomes more useful the more options exist on the menu.

The second skeptic is gentler. _Genetics explains less than you think it does. Tolerability, dosing, access, adherence, and phenotype matter more than SNPs for almost every patient._

This is the right skeptic, and the answer is to agree. Genetics is one layer. Not the only layer, not the dominant layer, not destiny. The clinical history a patient brings, the laboratory work the clinician runs, the lived response that emerges over months on a given molecule, and the priorities the patient articulates all matter at least as much as the genetic prior, and frequently more. The case for the genetics layer is not that it replaces the others. It is that it adds information that the others do not contain, at a marginal cost low enough to make adding it the rational move once the underlying menu has fragmented as much as it has.

* * *

9\. The End of the Sledgehammer Era

The Ozempic era is ending not because Ozempic failed, but because it succeeded. It established that obesity is a pharmacological problem, not a moral one. It moved the conversation in the span of two FDA decisions in a way that fifty years of behavioral medicine could not. None of that is undone by saying that the next generation of molecules is going to be more specialized, more precise, more matched to the underlying biology of the individual patient. It is the natural arc of every successful first-generation blockbuster.

The Ozempic era ends when one drug stops standing in for the entire future. By that definition, it is already over. What replaces it is not another single drug. It is the question we have been pointing at the whole time: _which molecule fits which biology, in which patient, optimizing for which axis?_

That question has many possible answers. Some of them are clinical, some of them are laboratory, some of them are lived experience, and some of them, increasingly, are written into a genome that has been quietly waiting to be asked.

* * *

FAQ

#### Is Ozempic actually being replaced, or is this just a thesis piece?

Both, but more the second than the first. Ozempic and Wegovy still account for the dominant share of GLP-1 prescriptions in 2026. The "replacement" being described here is not a one-for-one substitution at the prescription pad. It is a fragmentation of the category into specialized successors, each beating Ozempic on a different dimension.

#### How real is the 28.7% retatrutide weight-loss number?

It comes from Phase 3 trial data in the TRIUMPH program at the highest dose tested. Specific point estimates may shift as additional TRIUMPH readouts mature. The directional message ( retatrutide is achieving weight loss in the 25 to 30% range, approaching what bariatric surgery delivers) is robust enough that conservative readers should treat it as the current best estimate.

#### When will BRP be available as a therapy?

Not for several years. BRP is preclinical as of 2026. First-in-human safety trials are typically the next milestone, and the journey from there to a marketed therapy is, on average, the better part of a decade. Anyone selling BRP-based products in 2026 is selling something that does not yet exist as a validated therapeutic.

#### Do GLP-1 drugs really have anti-aging effects?

The honest answer is "the signal is real, the verdict is not yet in." Multi-omic studies have shown body-wide molecular changes consistent with broad anti- aging signatures. None of that constitutes proof of lifespan extension in humans, which would require trials specifically designed and powered for that endpoint.

#### Why does genetics matter more in a fragmented menu than in a monotherapy era?

Because the cost of mismatch rises with the number of options. In a one-drug world, the matching question is largely invisible. In a five-axis world, choosing wrong has a meaningful cost (a year on the wrong molecule, a side-effect profile that doesn't fit). That elevates the value of any decision-support layer that can shape the prior distribution from which the starting molecule is chosen.

#### What does the saliva DNA Kit actually measure?

The kit reads 111 SNPs with replicated associations across the metabolic and peptide-response pathways relevant to this category: incretin signaling, glucagon receptor variants, central appetite control loci, lipid handling, energy expenditure, muscle preservation, and cardiovascular protection signaling. The output, the Peptide Genetics Report, is structured around the matching problem rather than the marketing one.

#### Should I switch from Ozempic to one of these newer drugs?

That is a clinical decision and not one this article can make for any individual reader. If you are on Ozempic and it is working for you with tolerable side effects, the case for switching is weaker than if it is not working or the side effects are degrading your quality of life. The matching problem this article describes is a clinical conversation, not a self-prescribing one.

* * *

_Educational purposes only. This article is journalism and analysis, not medical advice. Decisions about starting, continuing, switching, or stopping any medication should be made in consultation with a licensed healthcare provider who knows your individual history. The Peptide List does not prescribe. The Peptide Genetics Report is a decision-support tool that adds biological context to a clinical conversation; it is not a substitute for clinical judgment. References to specific molecules, trials, and effect sizes reflect the published literature and trade reporting available as of April 2026 and may change as additional data publishes._

DNA Kit

Want to know which peptides match your genetics?

Our $250 DNA kit analyzes 111 SNPs across 15 pharmacogenes plus peptide-response markers. Get a personalized report on which peptides fit your biology.

Get your DNA kit

Free PDF Guide

Want the complete picture?

Download our free 56-page Essential Guide to Peptides. Covers the science, safety, and how to pick a legit provider.

Get the Free Guide

No spam. Unsubscribe anytime. We respect your privacy.

Ready to Find a Provider?

Browse our directory of verified peptide providers.

Browse Providers

This website is for informational purposes only and does not constitute medical advice. Consult a licensed physician before using any peptides. Provider listings do not constitute endorsements. None of the statements on this site have been evaluated by the FDA.